SLC2A4, solute carrier family 2 member 4, 6517

N. diseases: 158; N. variants: 7
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 AlteredExpression disease BEFREE Impaired expression of GLUT4 has been linked to insulin resistance and diabetes. 31806561 2020
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 AlteredExpression disease BEFREE These findings reveal the role of gallic acid in E. officinalis mediated antidiabetic potential, and delineate the upregulation of pAkt, PPAR-γ and Glut4 in gallic acid mediated antidiabetic activity, thus providing potential therapy for diabetes and related disorders. 31064680 2019
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 Biomarker disease BEFREE This study reveals that increased H3K9me3 in the Slc2a4 promoter enhancer segment contributes to reduce GLUT4 expression in skeletal muscle and to worse glycemic control in diabetes, pointing to the H3K9me3 of Slc2a4 promoter as a potential target for development of new approaches for treating diabetes. 30528377 2019
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 AlteredExpression disease BEFREE The compounds were tested in vitro against a set of four protein targets identified as key elements in diabetes: G protein-coupled receptor 40 (GPR40), aldose reductase (AKR1B1), peroxisome proliferator-activated receptor gama (PPARγ) and solute carrier family 2 (facilitated glucose transporter), member 4 (GLUT-4). 29415496 2018
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 Biomarker disease BEFREE The mAbs identified here will be valuable molecular tools for monitoring GLUT4 structure, function, and trafficking, for differentiating GLUT4 conformational states, and for the development of novel therapeutics for the treatment of diabetes. 29769329 2018
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 Biomarker disease BEFREE Defects in translocation of the glucose transporter GLUT4 are associated with peripheral insulin resistance, preclinical diabetes, and progression to type 2 diabetes. 28972183 2017
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 Biomarker disease BEFREE We suggest that sortilin- and retromer-mediated Glut4 retrieval from endosomes may represent a step in the Glut4 pathway vulnerable to the development of insulin resistance and diabetes. 28450454 2017
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 AlteredExpression disease BEFREE Understanding the interaction between insulin signaling molecules and key regulatory proteins that are involved in spatiotemporal regulation of GLUT4 vesicle exocytosis is of great importance to explain the pathogenesis of diabetes and may provide new potential therapeutic targets. 28529958 2017
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 Biomarker disease BEFREE Also, GLUT4, insulin receptor (IRβ), acetyl coenzyme A (ACC), etc. increased in fat pad of maternal offspring of diabetes. 28925477 2017
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 Biomarker disease BEFREE The inability of cells to mobilize the specific glucose transporter GLUT4 is believed to be at least partially accountable for diseases, like diabetes, where cells do not respond to an insulin stimulus. 28853753 2017
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 AlteredExpression disease BEFREE Insulin-mediated translocation of GLUT4 involves the PI3K/Akt kinase signal cascade that results in activation of endothelial NO synthase (eNOS). eNOS is dysfunctional during diabetes. 24157451 2014
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 Biomarker disease BEFREE Total GLUT4 content of the heart was decreased during diabetes, while there was no difference in total GLUT12. 23041416 2013
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 Biomarker disease BEFREE Yet, the role of adipose tissue GLUT4 deregulation in the pathogenesis of insulin resistance, obesity, and diabetes is still unclear. 21604201 2013
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 Biomarker disease BEFREE Downregulation of human and mouse adipose tissue GLUT4 occurs early in diabetes development. 22466288 2012
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 Biomarker disease BEFREE Our findings implicate the muscular GLUT4 system in the glucose intolerance of liver cirrhosis by a mechanism different from that in diabetes. 17448565 2007
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 AlteredExpression disease BEFREE We found the most sensitive and reliable molecular indicator of dioxin-induced diabetes to be the ratio of mRNA of glucose transporter 4 (GLUT4) and nuclear transcription factor kappa B (NFkappaB), a marker of inflammation. 17107852 2006
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 AlteredExpression disease BEFREE GLUT4 overexpression in db/db mice dose-dependently ameliorates diabetes but is not a lifelong cure. 11246879 2001
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 Biomarker disease BEFREE The hypothesis that altered metabolism plays a causative role in diabetes-induced contractile dysfunction was tested using perfused hearts from transgenic db/db mice that overexpress GLUT-4 glucose transporters. 11052966 2000
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 AlteredExpression disease BEFREE Myocyte enhancer factor 2 (MEF2)-binding site is required for GLUT4 gene expression in transgenic mice. Regulation of MEF2 DNA binding activity in insulin-deficient diabetes. 9603935 1998
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 Biomarker disease BEFREE The increase in muscle GLUT4 in trained individuals contributes to an increase in the responsiveness of muscle glucose uptake to insulin, although not all studies show that exercise training in patients with diabetes improves overall glucose control. 9509261 1998
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 AlteredExpression disease BEFREE GLUT4 expression is up-regulated by exercise training and thyroid hormone treatment and is down-regulated by fasting, streptozotocin-induced diabetes, obesity, high-fat diet, and denervation. 9405224 1997
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 AlteredExpression disease BEFREE 48 h fasting decreased GLUT-4 mRNA to 23% of control with restoration beginning by 6 h refeeding and full restoration at 24 h. In contrast, ob mRNA decreased less markedly to 47% of control with only partial restoration by 24 h. Two days of streptozocin (STZ)-diabetes (glucose > 400 mg/100 ml) decreased GLUT-4 mRNA to 8% of control with restoration by two days of S.C. insulin. 8607798 1996
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 AlteredExpression disease BEFREE In these animals, STZ-induced diabetes resulted in a parallel decrease in endogenous mouse GLUT4 mRNA and the transgenic human GLUT4 mRNA in white adipose tissue, brown adipose tissue, and cardiac muscle. 8486663 1993
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 AlteredExpression disease BEFREE There was no significant correlation between GLUT4 polypeptide levels and HbA1c, fasting plasma glucose, insulin, or free fatty acids, daily insulin dose, duration of diabetes, or subject age but in IDDM subjects GLUT4 protein levels correlated negatively with body mass index. 1569156 1992
CUI: C0011847
Disease: Diabetes
Diabetes
0.100 AlteredExpression disease BEFREE Suppression of GLUT 4 mRNA is observed in patients with impaired glucose tolerance, and therefore, may occur early in the evolution of diabetes. 1999488 1991